BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 17548607)

  • 1. Tumor-reactive CD4+ T cell responses to the melanoma-associated chondroitin sulphate proteoglycan in melanoma patients and healthy individuals in the absence of autoimmunity.
    Erfurt C; Sun Z; Haendle I; Schuler-Thurner B; Heirman C; Thielemans K; van der Bruggen P; Schuler G; Schultz ES
    J Immunol; 2007 Jun; 178(12):7703-9. PubMed ID: 17548607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Melanoma-associated chondroitin sulphate proteoglycan as a new target antigen for CD4+ T cells in melanoma patients.
    Erfurt C; Müller E; Emmerling S; Klotz C; Hertl M; Schuler G; Schultz ES
    Int J Cancer; 2009 May; 124(10):2341-6. PubMed ID: 19173283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of multiple HLA-DR-restricted epitopes of the tumor-associated antigen CAMEL by CD4+ Th1/Th2 lymphocytes.
    Slager EH; van der Minne CE; Krüse M; Krueger DD; Griffioen M; Osanto S
    J Immunol; 2004 Apr; 172(8):5095-102. PubMed ID: 15067093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional analysis of tumor-specific Th cell responses detected in melanoma patients after dendritic cell-based immunotherapy.
    Schultz ES; Schuler-Thurner B; Stroobant V; Jenne L; Berger TG; Thielemanns K; van der Bruggen P; Schuler G
    J Immunol; 2004 Jan; 172(2):1304-10. PubMed ID: 14707109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A HLA-DQ5 restricted Melan-A/MART-1 epitope presented by melanoma tumor cells to CD4+ T lymphocytes.
    Larrieu P; Ouisse LH; Guilloux Y; Jotereau F; Fonteneau JF
    Cancer Immunol Immunother; 2007 Oct; 56(10):1565-75. PubMed ID: 17318652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma.
    Mandic M; Castelli F; Janjic B; Almunia C; Andrade P; Gillet D; Brusic V; Kirkwood JM; Maillere B; Zarour HM
    J Immunol; 2005 Feb; 174(3):1751-9. PubMed ID: 15661941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen.
    Bluemel C; Hausmann S; Fluhr P; Sriskandarajah M; Stallcup WB; Baeuerle PA; Kufer P
    Cancer Immunol Immunother; 2010 Aug; 59(8):1197-209. PubMed ID: 20309546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heat shock protein 90-mediated peptide-selective presentation of cytosolic tumor antigen for direct recognition of tumors by CD4(+) T cells.
    Tsuji T; Matsuzaki J; Caballero OL; Jungbluth AA; Ritter G; Odunsi K; Old LJ; Gnjatic S
    J Immunol; 2012 Apr; 188(8):3851-8. PubMed ID: 22427632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD4+ Th2 cell recognition of HLA-DR-restricted epitopes derived from CAMEL: a tumor antigen translated in an alternative open reading frame.
    Slager EH; Borghi M; van der Minne CE; Aarnoudse CA; Havenga MJ; Schrier PI; Osanto S; Griffioen M
    J Immunol; 2003 Feb; 170(3):1490-7. PubMed ID: 12538712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers.
    Bioley G; Jandus C; Tuyaerts S; Rimoldi D; Kwok WW; Speiser DE; Tiercy JM; Thielemans K; Cerottini JC; Romero P
    J Immunol; 2006 Nov; 177(10):6769-79. PubMed ID: 17082590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Curatopes Melanoma: A Database of Predicted T-cell Epitopes from Overly Expressed Proteins in Metastatic Cutaneous Melanoma.
    Lischer C; Eberhardt M; Jaitly T; Schinzel C; Schaft N; Dörrie J; Schuler G; Vera J
    Cancer Res; 2019 Oct; 79(20):5452-5456. PubMed ID: 31416842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The alternative open reading frame of LAGE-1 gives rise to multiple promiscuous HLA-DR-restricted epitopes recognized by T-helper 1-type tumor-reactive CD4+ T cells.
    Mandic M; Almunia C; Vicel S; Gillet D; Janjic B; Coval K; Maillere B; Kirkwood JM; Zarour HM
    Cancer Res; 2003 Oct; 63(19):6506-15. PubMed ID: 14559844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells.
    Zarour HM; Maillere B; Brusic V; Coval K; Williams E; Pouvelle-Moratille S; Castelli F; Land S; Bennouna J; Logan T; Kirkwood JM
    Cancer Res; 2002 Jan; 62(1):213-8. PubMed ID: 11782380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a mutated receptor-like protein tyrosine phosphatase kappa as a novel, class II HLA-restricted melanoma antigen.
    Novellino L; Renkvist N; Rini F; Mazzocchi A; Rivoltini L; Greco A; Deho P; Squarcina P; Robbins PF; Parmiani G; Castelli C
    J Immunol; 2003 Jun; 170(12):6363-70. PubMed ID: 12794170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential immune escape and shifting of T cell responses in a long-term survivor of melanoma.
    Yamshchikov GV; Mullins DW; Chang CC; Ogino T; Thompson L; Presley J; Galavotti H; Aquila W; Deacon D; Ross W; Patterson JW; Engelhard VH; Ferrone S; Slingluff CL
    J Immunol; 2005 Jun; 174(11):6863-71. PubMed ID: 15905528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells.
    Zarour HM; Storkus WJ; Brusic V; Williams E; Kirkwood JM
    Cancer Res; 2000 Sep; 60(17):4946-52. PubMed ID: 10987311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recognition of a new ARTC1 peptide ligand uniquely expressed in tumor cells by antigen-specific CD4+ regulatory T cells.
    Wang HY; Peng G; Guo Z; Shevach EM; Wang RF
    J Immunol; 2005 Mar; 174(5):2661-70. PubMed ID: 15728473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular cloning of a human melanoma-associated chondroitin sulfate proteoglycan.
    Pluschke G; Vanek M; Evans A; Dittmar T; Schmid P; Itin P; Filardo EJ; Reisfeld RA
    Proc Natl Acad Sci U S A; 1996 Sep; 93(18):9710-5. PubMed ID: 8790396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-alpha.
    Tüting T; Wilson CC; Martin DM; Kasamon YL; Rowles J; Ma DI; Slingluff CL; Wagner SN; van der Bruggen P; Baar J; Lotze MT; Storkus WJ
    J Immunol; 1998 Feb; 160(3):1139-47. PubMed ID: 9570527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Normal tissue depresses while tumor tissue enhances human T cell responses in vivo to a novel self/tumor melanoma antigen, OA1.
    Touloukian CE; Leitner WW; Schnur RE; Robbins PF; Li Y; Southwood S; Sette A; Rosenberg SA; Restifo NP
    J Immunol; 2003 Feb; 170(3):1579-85. PubMed ID: 12538723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.